PepGen

PepGen Long-term Debt

Long-Term Debt of PepGen (PEPG) as of Nov 19, 2026.

Long-term Debt

-USD

Last updated:

Long-Term Debt of PepGen is 2026 - USD. Long-Term Debt of PepGen was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PepGen Stock analysis

What does PepGen do? PepGen Inc., based in Cambridge, Massachusetts, is a biotechnology company focused on developing oligonucleotide therapies for neuromuscular and neurologic diseases. The company utilizes its enhanced delivery oligonucleotide (EDO) platform, which employs cell-penetrating peptides to enhance therapeutic delivery. Its lead candidates, PGN-EDO51 for Duchenne muscular dystrophy and PGN-EDODM1 for myotonic dystrophy type 1, are part of a pipeline targeting degenerative conditions. Listed on 6 May 2022, PepGen operates with a team of 56 employees. PepGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PepGen stock

On Eulerpool you can find the complete historical development of Long-Term Debt PepGen since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's PepGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PepGen

All Key Metrics — PepGen